The capital structure is severely distressed, evidenced by an equity position that deteriorated to negative $16.1M as of 2025Q2 alongside an extremely low current ratio of 0.02.
| Total Current Assets | 192.08K | 3.47M | 271.72K | 202.71K | 129.56K | 830.77K |
| Cash & Short-Term Investments | 6.31K | 3.13M | 87.1K | 14.13K | 5.4K | 693.82K |
| Cash Only | 6.31K | 3.13M | 87.1K | 14.13K | 5.4K | 693.82K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 53.91K | 262.8K | 98.43K | 18.07K | 0 | 0 |
| Days Sales Outstanding | - | 187.95 | 102.61 | - | - | - |
| Inventory | 0 | 37.34K | 69.4K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | 38.39 | 128.8 | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 2.76M | 3.4M | 49.49K | 17.73M | 117.93M | 116.76M |
| Property, Plant & Equipment | 0 | 88.08K | 14.3K | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | 5.79x | 24.48x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 2.68M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 27.15M | 10.53M | 10.62K | 17.73M | 117.93M | 116.73M |
| Other Non-Current Assets | 0 | -9.9M | 0 | 0 | 0 | 23.29K |
| Total Assets | 2.95M | 6.86M | 321.21K | 17.93M | 118.06M | 117.59M |
| Asset Turnover | 0.00x | 0.07x | 1.09x | - | - | - |
| Asset Growth % | -194.53% | 2036.98% | -98.21% | -84.81% | 0.4% | - |
| Total Current Liabilities | 11.22M | 263.06K | 298.22K | 5.55M | 2M | 302.22K |
| Accounts Payable | 0 | 26.74K | 17.98K | 0 | 0 | 0 |
| Days Payables Outstanding | - | 27.5 | 33.36 | - | - | - |
| Short-Term Debt | 0 | 290 | 34.32K | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.15M | 0 | 344 | 5.55M | 2M | 302.22K |
| Current Ratio | 0.02x | 13.18x | 0.91x | 0.04x | 0.06x | 2.75x |
| Quick Ratio | 0.02x | 13.04x | 0.68x | 0.04x | 0.06x | 2.75x |
| Cash Conversion Cycle | - | 198.84 | 198.05 | - | - | - |
| Total Non-Current Liabilities | 7.79M | 10.92K | 2.2M | 1.18M | 7.11M | 17.51M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 5.68K | 5.68K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.46K | 1.46K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.79M | 3.77K | 2.2M | 1.18M | 7.11M | 17.51M |
| Total Liabilities | 19M | 273.98K | 298.22K | 6.74M | 9.11M | 17.81M |
| Total Debt | 0 | 22.55K | 47.58K | 0 | 0 | 0 |
| Net Debt | -6.31K | -3.11M | -39.52K | -14.13K | -5.4K | -693.82K |
| Debt / Equity | -0.00x | 0.00x | 2.07x | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - |
| Net Debt / EBITDA | 0.00x | - | - | -0.00x | -0.00x | - |
| Interest Coverage | - | -1893.69x | -4.59x | - | - | - |
| Total Equity | -16.05M | 6.59M | 22.99K | 11.2M | 108.96M | 99.78M |
| Equity Growth % | -64.62% | 28560.72% | -99.79% | -89.72% | 9.2% | - |
| Book Value per Share | -4.71 | 1.59 | 0.00 | 1.20 | 7.45 | 6.82 |
| Total Shareholders' Equity | -16.05M | 6.59M | 22.99K | 11.2M | 108.96M | 99.78M |
| Common Stock | 2.66M | 144.18K | 105.2K | 17.73M | 115M | 115M |
| Retained Earnings | -18.71M | -1.93M | -515.48K | -6.53M | -6.52M | -15.22M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 45.07K | 47.21K | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
Imminent liquidity insolvency risk
As reported in recent financial filings, YDES has seen its equity position deteriorate from a positive $3.0M in 2023Q4 to a negative $16.1M by 2025Q2, signaling a rapid erosion of shareholder value driven by persistent operating losses and aggressive capital allocation strategies.
The consistent decline into negative equity territory suggests that the company is consuming its capital base faster than it can generate value through its exosome platform. This trajectory warrants significant concern, as it indicates that the business model is currently unable to sustain its own operations without continuous external financing.
Based on the latest quarterly data, YDES maintains a precarious liquidity profile with cash reserves plummeting to just $6.3K in 2025Q2, a figure that appears insufficient to support the company's ongoing research and development activities or meet its immediate short-term liabilities.
The current ratio of 0.02 reflects a severe inability to cover current obligations, suggesting that the company is effectively operating on a day-to-day basis. Investors should monitor for emergency capital raises, as the current cash position provides virtually no buffer against operational shocks or unexpected clinical trial costs.
According to the balance sheet, the company's equity has been severely impacted by accumulated deficits totaling $18.7M as of 2025Q2, which highlights the significant financial strain placed on the firm by its high-cost, pre-revenue diagnostic development efforts.
The shift into negative equity suggests that the company has exhausted its initial capital and is now operating in a state of technical insolvency. This structure implies that any future funding will likely be highly dilutive to existing shareholders, as the firm lacks the retained earnings to support its own growth.
As indicated by historical balance sheet data, the company's total assets and liabilities have exhibited extreme volatility, with total liabilities spiking to $32.6M in 2024Q1 before contracting, which suggests that headline figures may be heavily influenced by non-recurring accounting adjustments rather than core operational growth.
The lack of consistent asset growth, combined with the absence of meaningful PPE, suggests that the company's value is tied entirely to intangible intellectual property that has yet to be validated commercially. Analysts should be wary of these fluctuations, as they may mask the underlying reality of a firm struggling to maintain a stable financial foundation.
Quick answers to the most common questions about buying YDES stock.
As of 2024, YD Bio Limited Ordinary Shares (YDES) had total assets of $6.9M including $3.5M in current assets.
YD Bio Limited Ordinary Shares (YDES) carries total debt of $0.0M, offset by $3.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
YD Bio Limited Ordinary Shares (YDES) has total shareholders' equity (book value) of $6.6M ($1.59 book value per share). Book value represents the net worth of the company belonging to common stock holders.
YD Bio Limited Ordinary Shares (YDES) reported a current ratio of 13.18x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.